Affiliation:
1. Mayo Clinic Health System, Austin, MN
Abstract
Abstract
OBJECTIVE
Using individual pharmacogenomic phenotypes to investigate the factors affecting the efficacy and tolerability of verapamil for migraine prevention.
BACKGROUND
Verapamil has a wide range of dosing in headache disorders without reliable tools to predict the optimal doses for an individual.
METHODS
This is a retrospective chart review examining adults with existing pharmacogenomic reports at Mayo Clinic who had used verapamil for migraine. Effects of six cytochrome P450 phenotypes on the minimum effective and maximum tolerable verapamil doses for migraine prevention were assessed.
RESULTS
The mean minimum effective and maximum tolerable doses for the 33 patients in final analysis were 178.2(20–320) mg and 227.9(20–480) mg. A variety of CYP2C9, CYP2D6, and CYP3A5 phenotypes were found, without significant association with the verapamil doses after adjusting for age, sex, body mass index, and smoking status.
CONCLUSIONS
We demonstrated a wide range of effective and tolerable verapamil doses used for migraine in a cohort with various pharmacogenomic phenotypes.
Publisher
Research Square Platform LLC
Reference26 articles.
1. The prevalence and impact of migraine and severe headache in the United States: Updated age, sex, and socioeconomic-specific estimates from government health surveys;Burch R;Headache,2021
2. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015;Collaborators GDaIIaP;Lancet,2016
3. Epidemiology, Burden, and Comorbidity;Burch RC;Neurol Clin,2019
4. Patterns of use and reasons for discontinuation of prophylactic medications for episodic migraine and chronic migraine: results from the second international burden of migraine study (IBMS-II);Blumenfeld AM;Headache,2013
5. Verapamil prophylaxis of migraine. A double-blind, placebo-controlled study;Solomon GD;Jama,1983